Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TKPHF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
tkphf · stock forecast · 5 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $30.47
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $29.67 | ↓ 2.63% |
1-day model range: $29.58–$29.76. Peak: $29.76 (-2.63%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $30 | -1.1% |
| 2028 | $30 | -1.9% |
| 2029 | $30 | -2.3% |
| 2030 | $30 | -2.6% |
| 2031 | — | -2.8% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · TKPHF · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-15 | TD Cowen | Maintains | Outperform→Outperform |
| 2023-04-03 | TD Cowen | Maintains | Outperform→Outperform |
| 2023-03-15 | B of A Securities | Upgrade ↑ | Neutral→Buy |
| 2022-07-18 | Cowen & Co. | Upgrade ↑ | Market Perform→Outperform |
| 2021-10-06 | Morgan Stanley | Downgrade ↓ | Overweight→Equal Weight |
| 2020-03-10 | JP Morgan | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Takeda Pharmaceutical Company Limited (TKPHF) stock. Of the recent 6 rating actions, 2 were upgrades and 1 were downgrades. 5 analysts currently cover TKPHF.
Analyst Recommendation Trends
TKPHF analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$4.61T
↓ 3.8% YoY
Revenue Next Year
$4.67T
↑ 1.3% YoY
EPS This Year
$138.62
EPS Next Year
$196.94
↑ 42.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast TKPHF EPS of $138.62 for the current fiscal year, based on estimates from 3 analysts. The TKPHF revenue forecast is $4.61T for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The TKPHF stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TKPHF price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The TKPHF short-term stock prediction for tomorrow is $29.67 (-2.63%). The TKPHF stock price prediction for 2027 estimates an average of $30. The TKPHF stock prediction for 2030 projects a range of $29–$31.
Takeda Pharmaceutical Company Limited trades on OTC under the ticker TKPHF. The TKPHF stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.
Frequently asked questions
TKPHF forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month TKPHF price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $30.47.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.